+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), Application, Region, and Segment Forecasts, 2025-2030- Product Image
Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), Application, Region, and Segment Forecasts, 2025-2030- Product Image
New

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), Application, Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 5702205
Description Jump to:
The global breast cancer liquid biopsy market size is expected to reach USD 1.90 billion in 2030 and is projected to grow at a CAGR of 8.5% from 2025 to 2030. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.

With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics’s subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.

Breast Cancer Liquid Biopsy Market Report Highlights

  • The circulating tumor cells (CTCs) segment is anticipated to grow at the fastest CAGR of 9.4% over the forecast period. There has been ongoing research to specify the utility of CTCs in early-stage breast cancer
  • The early detection/screening segment is expected to grow at a significant CAGR of 9.7% during the forecast period, due to the increasing application of the use of liquid biopsy in the early detection of cancer.
  • Based on application, the treatment selection segments led the market with the largest revenue share of 51.5% in 2024, attributed to the need to provide early treatment
  • North America dominated the breast cancer liquid biopsy market with the largest revenue share of 44.64% in 2024.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Breast Cancer Liquid Biopsy market include:

  • The Menarini Group
  • NeoGenomics Laboratories
  • F. Hoffmann - La Roche Ltd.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Biocept, Inc.
  • Sysmex Corporation
  • Fluxion Biosciences, Inc.
  • Epic Sciences, Inc.


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Circulating Biomarkers
1.2.2. Application
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Circulating Biomarkers outlook
2.2.2. Application outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Breast Cancer Liquid Biopsy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence Of Breast Cancer
3.2.1.2. Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
3.2.1.3. Need To Provide Early Diagnosis And Treatment
3.2.2. Market Restraint Analysis
3.2.2.1. High Cost Associated With Breast Cancer Liquid Biopsy Tests
3.2.2.2. Regulatory & Reimbursement Hurdles
3.3. Breast Cancer Liquid Biopsy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
4.3. Breast Cancer Liquid Biopsy Market by Circulating Biomarkers Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Circulating Tumor Cells (Ctcs)
4.4.1.1. Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.4.2. Circulating Cell - Free Dna (Cfdna)
4.4.2.1. Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.4.3. Extracellular Vesicles (Evs)
4.4.3.1. Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.4.4. Other Circulating Biomarkers
4.4.4.1. Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5. Breast Cancer Liquid Biopsy Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Breast Cancer Liquid Biopsy Market: Application Movement Analysis
5.3. Breast Cancer Liquid Biopsy Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Early Detection/Screening
5.4.1.1. Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.4.2. Diagnosis
5.4.2.1. Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.4.3. Treatment Selection
5.4.3.1. Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.4.4. Monitoring
5.4.4.1. Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6. Breast Cancer Liquid Biopsy Market: Regional Estimates & Trend Analysis
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Recent Developments & Impact Analysis by Key Market Participants
7.3. Key company market share, 2024
7.4. Key Company Profiles
7.4.1. The Menarini Group
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. NeoGenomics Laboratories
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. F. Hoffmann - La Roche Ltd.,
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Myriad Genetics, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Thermo Fisher Scientific, Inc.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. QIAGEN
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Biocept, Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Sysmex Corporation
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Fluxion Biosciences, Inc.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Epic Sciences, Inc.
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 4. Global Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 5. Global Breast Cancer Liquid Biopsy Market, by region, 2018 - 2030 (USD Million)
Table 6. North America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 7. North America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 8. U.S. Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 9. U.S. Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 10. Mexico Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 11. Mexico Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 12. Canada Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 13. Canada Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 14. Europe Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
Table 15. Europe Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 16. Europe Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 17. UK Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 18. UK Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 19. Germany Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 20. Germany Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 21. France Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 22. France Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 23. Italy Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 24. Italy Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 25. Spain Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 26. Spain Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 27. Denmark Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 28. Denmark Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 29. Norway Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 30. Norway Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 31. Sweden Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 32. Sweden Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 33. Asia Pacific Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
Table 34. Asia Pacific Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 35. Asia Pacific Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 36. Japan Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 37. Japan Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 38. China Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 39. China Breast Cancer Liquid Biopsy Market, by application 2018 - 2030 (USD Million)
Table 40. India Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 41. India Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 42. Australia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 43. Australia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 44. South Korea Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 45. South Korea Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 46. Thailand Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 47. Thailand Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 48. Latin America Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
Table 49. Latin America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 50. Latin America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 51. Brazil Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 52. Brazil Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 53. Argentina Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 54. Argentina Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 55. Middle East & Africa Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
Table 56. Middle East & Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 57. Middle East & Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 58. South Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 59. South Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 60. Saudi Arabia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 61. Saudi Arabia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 62. UAE Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 63. UAE Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
Table 64. Kuwait Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
Table 65. Kuwait Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information procurement
Fig. 2 Primary research pattern
Fig. 3 Market research approaches
Fig. 4 Value chain-based sizing & forecasting
Fig. 5 Market formulation & validation
Fig. 6 Breast Cancer Liquid Biopsy Market segmentation
Fig. 7 Market driver analysis (current & future impact)
Fig. 8 Market restraint analysis (current & future impact)
Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 10 Porter’s five forces analysis
Fig. 11 Breast Cancer Liquid Biopsy Market, Circulating Biomarkers outlook key takeaways (USD Million)
Fig. 12 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers movement analysis (USD Million), 2024 & 2030
Fig. 13 Circulating Tumor Cells (Ctcs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Circulating Cell - Free Dna (Cfdna) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 15 Extracellular Vesicles (Evs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 16 Other Circulating Biomarkers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Early Detection/Screening market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Diagnosis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Treatment Selection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Monitoring market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Breast Cancer Liquid Biopsy Market: regional key takeaways (USD Million)
Fig. 22 Breast Cancer Liquid Biopsy Market: regional outlook, 2023 & 2030, USD Million
Fig. 23 North America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 U.S. Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Canada Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Mexico Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Europe Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 UK Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Germany Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 France Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Spain Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Italy Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Norway Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Denmark Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Sweden Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Asia Pacific Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 China Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Japan Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 India Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 South Korea Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Australia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Thailand Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Latin America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Brazil Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Argentina Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Middle East and Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 South Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Saudi Arabia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 UAE Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Kuwait Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 List of key emerging company’s/liquid biopsy disruptors/innovators

Companies Mentioned

  • The Menarini Group
  • Neogenomics Laboratories
  • F. Hoffmann - La Roche Ltd.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen
  • Biocept, Inc.
  • Sysmex Corporation
  • Fluxion Biosciences, Inc.
  • Epic Sciences, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.17 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.9 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Testing Devices Market by Offerings, Circulating Biomarker, End-User, Appplication - Global Forecast 2025-2030 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market by Offerings, Circulating Biomarker, End-User, Appplication - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market by Biomarker, End-User - Global Forecast 2025-2030 - Product Image

Breast Cancer Liquid Biopsy Market by Biomarker, End-User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Breast Cancer Liquid Biopsy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Breast Cancer Liquid Biopsy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 115 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Report by Product Services, End User, and Region 2024-2032 - Product Image

Breast Cancer Liquid Biopsy Market Report by Product Services, End User, and Region 2024-2032

  • Report
  • 142 Pages
  • Global
From
Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker (Exosomes, CTC), Application (Cancer, Reproductive Health), Technology, Sample Type, Clinical Application, End-use, Product, Region, and Segment Forecasts, 2024-2030 - Product Image

Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker (Exosomes, CTC), Application (Cancer, Reproductive Health), Technology, Sample Type, Clinical Application, End-use, Product, Region, and Segment Forecasts, 2024-2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.